Synonyms: hPMAb22 [3] | PBP-1510 | PBP1510
Compound class:
Antibody
Comment: The INN record for ulenistamab identifies this as a hunamised monoclonal antibody directed against a protein called pancreatic adenocarcinoma up-regulated factor (PAUF). PAUF appears to be a product of the zymogen granule protein 16B gene ZG16B (UniProt accession Q96DA0), that is aberrantly expressed in some cancers [1,4], and which is involved in tumour development and metastasis [2]. The peptide sequences of the heavy and light chains of ulenistamab are claimed in patent WO2019022281A1 [3].
|
References |
1. Kim SA, Lee Y, Jung DE, Park KH, Park JY, Gang J, Jeon SB, Park EC, Kim YG, Lee B et al.. (2009)
Pancreatic adenocarcinoma up-regulated factor (PAUF), a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. Cancer Sci, 100 (5): 828-36. [PMID:19302292] |
2. Kim SJ, Chang S, Lee Y, Kim NY, Hwang Y, Min HJ, Yoo KS, Park EH, Kim S, Chung YH et al.. (2014)
A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. Biochem Biophys Res Commun, 454 (1): 144-50. [PMID:25450371] |
3. Koh S-s, Kim Y-j, Yoon S-e, Kim S-c, Hong S-m, Jeong S-y. (2019)
Antibody specifically binding to pauf protein, and use thereof. Patent number: WO2019022281A1. Assignee: Dong-A University Industry Cooperation Foundation, Prestige Biopharma. Priority date: 28/07/2017. Publication date: 31/01/2019. |
4. Lu H, Shi C, Liu X, Liang C, Yang C, Wan X, Li L, Liu Y. (2021)
Identification of ZG16B as a prognostic biomarker in breast cancer. Open Med (Wars), 16 (1): 1-13. [PMID:33336077] |